{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T17:25:23Z","timestamp":1791998723220,"version":"4.4.0"},"reference-count":45,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T00:00:00Z","timestamp":1761609600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Ribavirin is a broad-spectrum antiviral drug used to treat chronic hepatitis C, respiratory syncytial virus infections, and other viral diseases. However, its clinical use is often limited by adverse events, including hemolytic anemia, gastrointestinal disturbances, and neurological symptoms, which negatively affect treatment adherence and patient well-being. Nursing interventions are essential in mitigating these adverse events through early assessment, symptom management, patient education, and multidisciplinary collaboration, ultimately improving patient outcomes. Current evidence shows that nursing interventions significantly improve treatment efficacy and quality of life. However, challenges persist, such as individual patient variability, resource constraints, and insufficient evidence-based guidelines. Future research should focus on establishing standardized nursing protocols, conducting multicenter clinical studies, exploring intelligent nursing approaches, and enhancing nursing expertise to optimize ribavirin-related adverse event management.<\/jats:p>","DOI":"10.3389\/fphar.2025.1596007","type":"journal-article","created":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T06:25:52Z","timestamp":1761632752000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Advances in clinical application on nursing intervention for ribavirin-associated adverse events"],"prefix":"10.3389","volume":"16","author":[{"given":"Li-Li","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Xin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-Hui","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.coviro.2014.04.011","article-title":"Ribavirin: a drug active against many viruses with multiple effects on virus replication and propagation. Molecular basis of ribavirin resistance","volume":"8","author":"Beaucourt","year":"2014","journal-title":"Curr. Opin. Virol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"6195","DOI":"10.3748\/wjg.14.6195","article-title":"Patient education improves adherence to peg-interferon and ribavirin in chronic genotype 2 or 3 hepatitis C virus infection: a prospective, real-life, observational study","volume":"14","author":"Cacoub","year":"2008","journal-title":"World J. Gastroenterol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.jhep.2020.10.013","article-title":"EASL recommendations on treatment of hepatitis C: final update of the series - some issues","volume":"74","author":"Dai","year":"2021","journal-title":"J. Hepatol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1016\/j.bcp.2013.09.010","article-title":"Dancing with chemical formulae of antivirals: a panoramic view (part 2)","volume":"86","author":"De Clercq","year":"2013","journal-title":"Biochem. Pharmacol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1053\/he.2000.5789","article-title":"Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage","volume":"31","author":"De Franceschi","year":"2000","journal-title":"Hepatology"},{"key":"B6","doi-asserted-by":"publisher","first-page":"e001161","DOI":"10.1136\/bmjoq-2020-001161","article-title":"Preventable adverse drug events causing hospitalisation: identifying root causes and developing a surveillance and learning system at an urban community hospital, a cross-sectional observational study","volume":"10","author":"de Lemos","year":"2021","journal-title":"BMJ Open Qual."},{"key":"B7","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1136\/qshc.2007.023622","article-title":"The incidence and nature of in-hospital adverse events: a systematic review","volume":"17","author":"de Vries","year":"2008","journal-title":"Qual. Saf. Health Care"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/01.nurse.0000461850.24153.8b","article-title":"The nurse's role in medication safety","volume":"45","author":"Durham","year":"2015","journal-title":"Nursing"},{"key":"B9","first-page":"82","article-title":"Traditional Chinese medicine nursing experience for adverse reactions of long-acting interferon combined with ribavirin in the treatment of chronic hepatitis C","volume":"8","author":"Fan","year":"2016","journal-title":"Clin. J. Chin. Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/nature08825","article-title":"ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C","volume":"464","author":"Fellay","year":"2010","journal-title":"Nature"},{"key":"B11","first-page":"133","article-title":"Observation and nursing of adverse reactions during antiviral therapy in patients with chronic hepatitis C","volume":"32","author":"Feng","year":"2015","journal-title":"J. Chengde Med. Coll."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1089\/jpm.2018.0431","article-title":"National consensus project clinical practice guidelines for quality palliative care guidelines, 4th edition","volume":"21","author":"Ferrell","year":"2018","journal-title":"J. Palliat. Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"58","DOI":"10.7869\/tg.2012.99","article-title":"Chronic hepatitis C-associated thrombocytopenia: aetiology and management","volume":"34","author":"Fouad","year":"2013","journal-title":"Trop. Gastroenterol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"545","DOI":"10.2165\/00002018-200831060-00009","article-title":"Prevalence, clinical features and avoidability of adverse drug reactions as cause of admission to a geriatric unit: a prospective study of 1756 patients","volume":"31","author":"Franceschi","year":"2008","journal-title":"Drug Saf."},{"key":"B15","doi-asserted-by":"publisher","first-page":"346","DOI":"10.7326\/0003-4819-140-5-200403020-00010","article-title":"Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose","volume":"140","author":"Hadziyannis","year":"2004","journal-title":"Ann. Intern Med."},{"key":"B16","first-page":"1013","article-title":"Adverse reactions and nursing care of pegylated interferon \u03b1-2a combined with ribavirin in the treatment of chronic hepatitis C","volume":"15","author":"He","year":"2012","journal-title":"Chin. Pharm."},{"key":"B17","first-page":"288","article-title":"Nursing strategies for adverse reactions caused by interferon combined with ribavirin in the treatment of hepatitis C","volume":"7","author":"Hui","year":"2010","journal-title":"Anti-Infec Pharm."},{"key":"B18","first-page":"1998","article-title":"Clinical efficacy observation and nursing intervention of pegylated interferon \u03b1-2a injection combined with ribavirin in the treatment of chronic hepatitis C","volume":"45","author":"Jia","year":"2021","journal-title":"Guizhou Med. J."},{"key":"B19","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/j.cgh.2011.05.022","article-title":"Education by a nurse increases response of patients with chronic hepatitis C to therapy with peginterferon-\u03b12a and ribavirin","volume":"9","author":"Larrey","year":"2011","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"B20","first-page":"47","article-title":"Observation and nursing of adverse reactions in the treatment of chronic hepatitis C virus with Pegasys combined with ribavirin","author":"Liu","year":"2017","journal-title":"Women's Health Res."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1016\/j.cmi.2023.04.021","article-title":"Ribavirin treatment for respiratory syncytial virus infection in patients with haematologic malignancy and haematopoietic stem cell transplant recipients: a systematic review and meta-analysis","volume":"29","author":"Manothummetha","year":"2023","journal-title":"Clin. Microbiol. Infect."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1053\/gast.2002.35950","article-title":"Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C","volume":"123","author":"McHutchison","year":"2002","journal-title":"Gastroenterology"},{"key":"B23","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.gtc.2010.08.008","article-title":"Pharmacokinetics and pharmacodynamics of peginterferon and ribavirin: implications for clinical efficacy in the treatment of chronic hepatitis C","volume":"39","author":"Noureddin","year":"2010","journal-title":"Gastroenterol. Clin. North Am."},{"key":"B24","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1053\/j.gastro.2016.04.003","article-title":"Hepatitis C virus resistance to direct-acting antiviral drugs in interferon-free regimens","volume":"151","author":"Pawlotsky","year":"2016","journal-title":"Gastroenterology"},{"key":"B25","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1071\/AH12027","article-title":"Hospital admissions caused by adverse drug events: an Australian prospective study","volume":"38","author":"Phillips","year":"2014","journal-title":"Aust. Health Rev."},{"key":"B26","first-page":"715","article-title":"Treatment of hepatitis C virus genotype 3 infection","volume":"11","author":"Poordad","year":"2015","journal-title":"Gastroenterol. Hepatol. (N Y)."},{"key":"B27","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.cgh.2006.10.008","article-title":"Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a\/ribavirin treatment","volume":"5","author":"Reddy","year":"2007","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"3351","DOI":"10.2174\/092986706778773059","article-title":"Ribavirin-induced anemia: mechanisms, risk factors and related targets for future research","volume":"13","author":"Russmann","year":"2006","journal-title":"Curr. Med. Chem."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1016\/s0016-5085(03)00394-9","article-title":"Side effects of therapy for chronic hepatitis C","volume":"124","author":"Russo","year":"2003","journal-title":"Gastroenterology"},{"key":"B30","doi-asserted-by":"publisher","first-page":"65","DOI":"10.3350\/cmh.2018.0070","article-title":"Efficacy of L-carnitine on ribavirin-induced hemolytic anemia in patients with hepatitis C virus infection","volume":"25","author":"Sato","year":"2019","journal-title":"Clin. Mol. Hepatol."},{"key":"B31","first-page":"125","article-title":"Managing adverse effects and complications in completing treatment for hepatitis C virus infection","volume":"20","author":"Sherman","year":"2012","journal-title":"Top. Antivir. Med."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1007\/s40264-017-0566-6","article-title":"The ribavirin pregnancy registry: an interim analysis of potential teratogenicity at the mid-point of enrollment","volume":"40","author":"Sinclair","year":"2017","journal-title":"Drug Saf."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1517\/14656566.2.8.1317","article-title":"Ribavirin--current status of a broad spectrum antiviral agent","volume":"2","author":"Snell","year":"2001","journal-title":"Expert Opin. Pharmacother."},{"key":"B34","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1111\/j.1365-2893.2004.00490.x","article-title":"Changes in haemoglobin during interferon alpha-2b plus ribavirin combination therapy for chronic hepatitis C virus infection","volume":"11","author":"Sulkowski","year":"2004","journal-title":"J. Viral Hepat."},{"key":"B35","doi-asserted-by":"publisher","first-page":"155","DOI":"10.13586\/j.cnki.yjyx1984.2021.02.023","article-title":"Comprehensive nursing experience of pegylated interferon combined with ribavirin in the treatment of chronic hepatitis C","volume":"38","author":"Sun","year":"2021","journal-title":"Chin. J. Med. Metall."},{"key":"B36","first-page":"717","article-title":"Observation and nursing of adverse reactions in the treatment of chronic hepatitis C with pegylated interferon combined with ribavirin","volume":"25","author":"Tan","year":"2011","journal-title":"Chin. Nurs. Res."},{"key":"B37","doi-asserted-by":"publisher","first-page":"4037","DOI":"10.1007\/s12325-022-02256-5","article-title":"Ribavirin for treatment of subjects with respiratory syncytial virus-related infection: a systematic review and meta-analysis","volume":"39","author":"Tejada","year":"2022","journal-title":"Adv. Ther."},{"key":"B38","article-title":"The evidence for evidence-based practice implementation","volume-title":"Patient safety and quality: an evidence-based handbook for nurses","author":"Titler","year":"2008"},{"key":"B39","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.3390\/ijerph17062028","article-title":"Nurses' adherence to patient safety principles: a systematic review","volume":"17","author":"Vaismoradi","year":"2020","journal-title":"Int. J. Environ. Res. Public Health"},{"key":"B40","doi-asserted-by":"publisher","first-page":"ofae155","DOI":"10.1093\/ofid\/ofae155","article-title":"Hepatitis C virus antiviral drug resistance and salvage therapy outcomes across Australia","volume":"11","author":"Wang","year":"2024","journal-title":"Open Forum Infect. Dis."},{"key":"B41","doi-asserted-by":"publisher","first-page":"e5504","DOI":"10.1590\/1414-431X20165504","article-title":"Treatment of hepatitis C virus genotype 3 infection with direct-acting antiviral agents","volume":"49","author":"Zanaga","year":"2016","journal-title":"Braz J. Med. Biol. Res."},{"key":"B42","first-page":"2273","article-title":"Nursing care for adverse reactions caused by interferon combined with ribavirin in the treatment of chronic hepatitis C","volume":"13","author":"Zhang","year":"2015","journal-title":"Chin. Gen. Pract. Nurs."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.14053\/j.cnki.ppcr.2013.11.005","article-title":"Observation and nursing of adverse reactions in the treatment of chronic hepatitis C with Pegasys combined with ribavirin","volume":"16","author":"Zhang","year":"2013","journal-title":"Pract. Pharm. Clin. Remed."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.16821\/j.cnki.hsjx.2014.19.041","article-title":"Observation and nursing of adverse drug reactions in the treatment of chronic hepatitis C with interferon combined with ribavirin","volume":"29","author":"Zhang","year":"2014","journal-title":"J. Nurses Train."},{"key":"B45","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s40506-017-0136-6","article-title":"Retreatment options following HCV direct acting antiviral failure","volume":"9","author":"Zuckerman","year":"2017","journal-title":"Curr. Treat. Options Infect. Dis."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1596007\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T06:25:57Z","timestamp":1761632757000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1596007\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,28]]},"references-count":45,"alternative-id":["10.3389\/fphar.2025.1596007"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1596007","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,28]]},"article-number":"1596007"}}